Drugs / SLS-002
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06816433 | May 2028 → May 2029 | post-traumatic stress disorder | Global Coalition for Adaptive Research | Suspended | No outcome recorded |
| Phase 2 | NCT05422612 | Nov 2023 → Jul 2028 | post-traumatic stress disorder | Global Coalition for Adaptive Research | Suspended | No outcome recorded |
| Phase 2 | NCT04669665 | Dec 2020 → Jun 2023 | major depressive disorder | Seelos Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLS-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06816433 ↗ |
| Route | Intranasal | “administered via intranasal administration” NCT05422612 ↗ |